Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8339739 | 0.87 | IDO1 (0.38) | MAOBGABRB2USP2 | |
| SCHEMBL4900102 | 0.87 | IDO1 (0.43) | KMT2AMEN1HSD17B10ALDH1A1MAOB | |
| SCHEMBL4912762 | 0.87 | IDO1 (0.43) | KMT2AMEN1HSD17B10ALDH1A1MAOB | |
| SCHEMBL4906121 | 0.80 | ABCB1 (0.40) | KMT2AMEN1ABCB1ARABCG2 | |
| SCHEMBL3341036 | 0.79 | SMN1; SMN2 (0.54) | KMT2AMEN1ABCB1ARABCG2 | |
| SCHEMBL4897648 | 0.79 | SMN1; SMN2 (0.54) | KMT2AMEN1ABCB1ARABCG2 | |
| SCHEMBL14260850 | 0.76 | IDO1 (0.45) | KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL17324441 | 0.76 | GAA (0.49) | HSD17B10 | |
| SCHEMBL29467169 | 0.76 | GAA (0.49) | HSD17B10 | |
| SCHEMBL18419871 | 0.76 | GAA (0.49) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080311609-A1 | Novel Molecular Probes | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1831187-A1 | NOVEL MOLECULAR PROBES | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065218-A1 | NOVEL MOLECULAR PROBES | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311609-A1 | Novel Molecular Probes | BACE1, BACE2, PSEN1 | KMT2A 4557/4885MEN1 2630/4885ABCB1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.